ClinicalTrials.gg
CompletedNCT00191984Updated Jan 5, 2011Results posted

A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer

A Phase 2 interventional study of pemetrexed and irinotecan in Metastatic Colorectal Cancer, sponsored by Eli Lilly and Company. Completed at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-05.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing pemetrexed in Colorectal Neoplasms — none open to participants now, none under way, none of them phase 3. Pemetrexed · Colorectal Neoplasms.

Started
2004
with 1 other
Phase 2
8 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
4 of 10
Eli Lilly and Company

Among the 10 studies testing pemetrexed in Colorectal Neoplasms, this one is one of 2 that started in 2004, is one of 8 in phase 2, and was the 4th registered.

Colorectal Neoplasms

6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

None of the 10 studies testing pemetrexed in Colorectal Neoplasms is open now. The open studies under Colorectal Neoplasms, anywhere →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing pemetrexed in Colorectal Neoplasms as a file.
02

Study summary

A non-randomized phase II study to determine the efficacy and safety of the combination of Pemetrexed and Irinotecan every two weeks in metastatic colorectal cancer patients.

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of colorectal adenocarcinoma that is not amenable to curative therapy.
  • Patient must have at least one unidimensionally .
  • Prior radiation therapy to less than 25% of bone marrow. Radiation must be completed at least 4 weeks prior to study enrollment.
  • Performance status 0 to 2
  • Patient must have received 1 prior course of chemotherapy (Folfox regimen) for metastatic disease

Exclusion criteria

Exclusion Criteria:

  • Treatment with any drug within the last 30 days that has not received regulatory approval.
  • Serious systemic disorder (cardiac or pulmonary disease, active infection)
  • Documented not amenable to surgery or unstable after radiation
  • Inability or unwillingness to take folic acid or Vitamin B12 supplementation.
  • Presence of fluid retention that can not be controlled by drainage.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Pemetrexed + Irinotecan

    Drug: pemetrexed · Drug: irinotecan

Interventions

  • 400 mg/m\^2, intravenous (IV), every 14 days x 12 cycles

    Also known as: LY231514, Alimta

  • 180 mg/m\^2, intravenous (IV), every 14 days x 12 cycles

06

What researchers measure

Primary outcomes

  1. Best Overall Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.

    Time frame: baseline to measured progressive disease (up to 2 years follow-up)

Secondary outcomes

  1. Duration of Response

    The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.

    Time frame: time of response to progressive disease or death (up to 2 years follow-up)

  2. Progression-Free Survival (PFS)

    Defined as the time from study enrollment to the first date of disease progression or death as a result of any cause. PFS was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed.

    Time frame: baseline to measured progressive disease or death (up to 2 years follow-up)

  3. Time to Treatment Failure

    Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.

    Time frame: baseline to stopping treatment (up to 2 years follow-up)

  4. Overall Survival

    Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

    Time frame: baseline to date of death from any cause (up to 2 years follow-up)

07

Results

Posted Jun 15, 2009

Participant flow

Participant flow — Overall Study
MilestonePemetrexed + Irinotecan
Started46
Completed7
Not completed39
Withdrew: Disease progression21
Withdrew: Adverse event4
Withdrew: Death2
Withdrew: Entry criteria exclusion1
Withdrew: Withdrawal by subject7
Withdrew: Physician decision4

Outcome measures

PrimaryBest Overall Tumor Response

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions. Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) = small changes that do not meet above criteria.

Time frame:
baseline to measured progressive disease (up to 2 years follow-up)
Reported as:
Number · participants
Best Overall Tumor Response
participantsPemetrexed + Irinotecan
Partial Response6
Stable Disease18
Progressive Disease15
Unknown5
SecondaryDuration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions. Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions.

Time frame:
time of response to progressive disease or death (up to 2 years follow-up)
Reported as:
Median · days
Duration of Response
daysPemetrexed + Irinotecan
Duration of Response236 (105 to 353)
SecondaryProgression-Free Survival (PFS)

Defined as the time from study enrollment to the first date of disease progression or death as a result of any cause. PFS was censored at the date of the last follow-up visit for participants who were still alive and who had not progressed.

Time frame:
baseline to measured progressive disease or death (up to 2 years follow-up)
Reported as:
Median · days
Progression-Free Survival (PFS)
daysPemetrexed + Irinotecan
Progression-Free Survival (PFS)123 (60 to 146)
SecondaryTime to Treatment Failure

Defined as the time from study enrollment to the first observation of disease progression, death as a result of any cause, or early discontinuation of treatment. Time to treatment failure was censored at the date of the last follow-up visit for patients who did not discontinue early, who were still alive, and who have not progressed.

Time frame:
baseline to stopping treatment (up to 2 years follow-up)
Reported as:
Median · days
Time to Treatment Failure
daysPemetrexed + Irinotecan
Time to Treatment Failure66 (55 to 105)
SecondaryOverall Survival

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact.

Time frame:
baseline to date of death from any cause (up to 2 years follow-up)
Reported as:
Median · days
Overall Survival
daysPemetrexed + Irinotecan
Overall Survival422 (305 to 602)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed + Irinotecan———
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPemetrexed + Irinotecan
AnaemiaBlood and lymphatic system disorders3/44
DiarrhoeaGastrointestinal disorders3/44
VomitingGastrointestinal disorders2/44
DehydrationMetabolism and nutrition disorders2/44
DyspnoeaRespiratory, thoracic and mediastinal disorders2/44
Febrile neutropeniaBlood and lymphatic system disorders1/44
MelaenaGastrointestinal disorders1/44
NauseaGastrointestinal disorders1/44
AstheniaGeneral disorders1/44
General physical health deteriorationGeneral disorders1/44
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPemetrexed + Irinotecan
AstheniaGeneral disorders24/44
NauseaGastrointestinal disorders18/44
DiarrhoeaGastrointestinal disorders15/44
VomitingGastrointestinal disorders11/44
AnaemiaBlood and lymphatic system disorders10/44
Weight decreasedInvestigations9/44
ConstipationGastrointestinal disorders8/44
AnorexiaMetabolism and nutrition disorders8/44
NeutropeniaBlood and lymphatic system disorders7/44
Abdominal painGastrointestinal disorders6/44

Baseline characteristics

Age Continuous
Age Continuous(years)Pemetrexed + Irinotecan
Mean60.8 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed + Irinotecan
Female13
Male31
Region of Enrollment
Region of Enrollment(participants)Pemetrexed + Irinotecan
France44
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(units on a scale)Pemetrexed + Irinotecan
0 - Fully Active24
1 - Ambulatory, Restricted Strenuous Activity15
2 - Ambulatory, No Work Activities5
Pathological Diagnosis
Pathological Diagnosis(participants)Pemetrexed + Irinotecan
Adenocarcinoma of Colon22
Adenocarcinoma of Rectum20
Colorectal Cancer2
Height
Height(centimeters)Pemetrexed + Irinotecan
Mean169.3 ± 8.5
Weight
Weight(kilograms)Pemetrexed + Irinotecan
Mean69.3 ± 11.7
08

Study locations

5 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Angers, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Lille, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Montfermeil, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Paris, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Suresnes, France
09

References and documents

Publications

  • Louvet C, Andre T, Gamelin E, Hebbar M, Mabro M, Bennamoun M, Rassam H, de Gramont A. Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer. J Oncol. 2010;2010:785934. doi: 10.1155/2010/785934. Epub 2010 Apr 8. PubMed 20396391 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Feb 2007 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Jun 2004
Primary completionActual
Feb 2007
CompletionActual
May 2008
Results first posted
Jun 15, 2009
Last update
Jan 5, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00191984
First posted
Sep 19, 2005
Start date
Jun 2004
Primary completion
Feb 2007
Completion
May 2008
Results posted
Jun 15, 2009
Last update
Jan 5, 2011

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Irinotecan

Start the discussion